Sol-Gel将向PellePharm支付470万美元的预付款,以及高达600万美元的开发和NDA验收里程碑,以及高达6400万美元的商业里程碑和分成。
Patidegib被Sol-Gel指定为SGT-610,用于治疗Go...查看全文
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001844 Act: 34 Size: 55 KB 网页链接
$Sol-gel(SLGL)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001178913-24-001788 Act: 33 Size: 192 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001778 Act: 34 Size: 147 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001757 Act: 34 Size: 576 KB 网页链接
$Sol-gel(SLGL)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001178913-24-001246 Act: 34 Size: 55 KB 网页链接
$Sol-gel(SLGL)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001178913-24-001220 Act: 33 Size: 320 KB 网页链接
$Sol-gel(SLGL)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-000805 Act: 33 Size: 1 KB 网页链接
$Sol-gel(SLGL)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001178913-24-001166 Act: 34 Size: 562 KB 网页链接
$Sol-gel(SLGL)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001178913-24-001006 Act: 33 Size: 436 KB 网页链接
$Sol-gel(SLGL)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001178913-24-000932 Act: 34 Size: 10 MB 网页链接